| A Phase 3, Randomized, Double-Blind,Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease |
Ongoing |
Tulisokibart |
3 |
NCT0643080 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Hospital NG (Riyadh), King Saud University Medical City (Riyadh), King Abdullah Medical City Specialist Hospital (Makkah) |
| Prospective multi-country, real-world, multi-arm study of treatment PErsistence with RISankizumab in Psoriatic Arthritis |
Ongoing |
Risankizumab (Skyrizi®) |
4 |
P24-390 |
King Fahad Medical City (Riyadh) |
| An Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis with Moderate-to-Severe Pruritus |
Ongoing |
Difelikefalin |
2 |
KOR-PED-202 |
King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah) |
| A Phase 2 / Phase 3, Multicenter, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Adaptive Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis |
Ongoing |
CSL889 |
3 |
CSL889_2001 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Khalid University Hospital (Riyadh), Prince Mohammad Bin Naser Hospital (Jazan) |
| A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study To Assess The Efficacy And Safety of Induction and Maintenance Therapy with Ro7790121 in Patients with Moderately to Severely Active Crohn's Disease |
Ongoing |
Ro7790121 |
3 |
GA45331 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Saud Medical City (Riyadh) |
| Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies |
Ongoing |
Eculizumab |
3 |
ALXN-MG-50 |
Aseer Hospital (Abha), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| A randomized, double-blinded placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of Efgartigimod PH20 SC Administered by prefilled syringe in adults participants with ocular MG |
Ongoing |
Efgartigimod |
3 |
ARGX-113-2315 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease |
Ongoing |
Efgartigimod |
3 |
ARGX-113-2306 |
King Faisal Specialist Hospital and Research Center (Riyadh) , King Khalid University Hospital (Riyadh) |
| A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) |
Ongoing |
Rapcabtagene Autoleucel (YTB323) |
2 |
CYTB323I12201 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH) |
Ongoing |
Seralutinib |
3 |
GB002-3102 |
King Faisal Specialist Hospital and Research Center (Riyadh) , King Fahad Medical City (Riyadh) |
